ArticleBalkan journal of medical genetics : BJMG2026
Application of Fluorescence in situ Hybridization in Malignant Hemopathies: First Experience from Albania.
Article in Balkan journal of medical genetics : BJMG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Genetic alterations in genome organization are essential for the clinical evaluation of hematological disorders. Fluorescence in situ hybridization (FISH) enables the detection and determination of the frequency of genetic abnormalities. Objectives: This study aims to apply selected probes as a diagnostic approach to aid in establishing diagnosis, predicting prognosis, and monitoring disease progression. Results: Fluorescence microscopy analysis of inter-phase cells was undertaken at the Laboratory of Molecular Cytogenetics, within the Clinical Genetics Laboratory Service, in a cohort of 330 adult patients with hematological disorders clinically established by the Hematology Service at QSU "Mother Teresa," Tirana, Albania.Detection of the Conclusions: Through the identification of specific genetic mutations, molecular cytogenetics contributes to early diagnosis, improving the prognosis and choosing the most appropriate treatments, significantly improving the survival and quality of patient's life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.